Myeloid somatic mutation panel testing in myeloproliferative neoplasms
Files
(Published version)
Date
2021
Authors
Ross, D.M.
Thomson, C.
Hamad, N.
Lane, S.W.
Manos, K.
Grigg, A.P.
Guo, B.
Erber, W.N.
Scott, A.
Viiala, N.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Pathology, 2021; 53(3):339-348
Statement of Responsibility
Conference Name
Abstract
Myeloproliferative neoplasms are characterised by somatic mutations in pathways that regulate cell proliferation, epigenetic modifications, RNA splicing or DNA repair. Assessment of the mutational profile assists diagnosis and classification, but also aids assessment of prognosis, and may guide the use of emerging targeted therapies. The most practical way to provide information on numerous genetic variants is by using massively parallel sequencing, commonly in the form of disease specific next generation sequencing (NGS) panels. This review summarises the diagnostic and prognostic value of somatic mutation testing in Philadelphia-negative myeloproliferative neoplasms: polycythaemia vera, essential thrombocythaemia, primary myelofibrosis, chronic neutrophilic leukaemia, systemic mastocytosis, and chronic eosinophilic leukaemia. NGS panel testing is increasing in routine practice and promises to improve the accuracy and efficiency of pathological diagnosis and prognosis.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Crown Copyright 2021 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia
Access Condition Notes: Published version available after 1 April 2021